Summary Dipyridamole has been shown to enhance the in vitro activity of antimetabolite anticancer drugs through the inhibition of nucleoside transport. However, the clinical potential of dipyridamole has not been realized because of the avid binding of the drug to the plasma protein α 1 -acid glycoprotein (AGP). Dipyridamole analogues that retain potent nucleoside transport inhibitory activity in the presence of AGP are described and their ability to enhance the growth inhibitory and cytotoxic effects of thymidylate synthase (TS) inhibitors has been evaluated. Three dipyridamole analogues (NU3026, NU3059 and NU3060) were shown to enhance the growth inhibitory activity of the TS inhibitor CB3717 and block thymidine rescue in L1210 cells. The extent of potentiation at a fixed analogue concentration (10 µM) was related to the potency of inhibition of thymidine uptake. A further analogue, NU3076, was identified, which was more potent than dipyridamole with a K i value for inhibition of thymidine uptake of 0.1 µM compared to 0.28 µM for dipyridamole. In marked contrast to dipyridamole, inhibition of thymidine uptake by NU3076 was not significantly affected by the presence of AGP (5 mg ml -1
Antimetabolite inhibitors of de novo purine and pyrimidine synthesis are used extensively in cancer chemotherapeutic regimes (Schilsky, 1992) . In particular, inhibition of thymidylate synthase (TS) is an attractive target for antimetabolite chemotherapy because thymine is the only nucleobase found exclusively in DNA and TS is a key enzyme, possibly the rate-limiting step, in DNA synthesis. One locus of action of 5-fluorouracil (5-FU), which is widely used for the treatment of colorectal, breast and head-andneck cancer, is TS inhibition following its intracellular conversion to 5-FdUMP. CB3717 (N 10 -propargyl-5,8-dideazafolate) was the first selective antifolate inhibitor of TS to be developed (Jones et al, 1981) , and in early clinical trials with CB3717 promising therapeutic activity was reported (Calvert et al, 1986) . More recently, a number of antifolate TS inhibitors have been developed, i.e. raltitrexed, nolatrexed, MTA, AG 331, BW 1843 U89 and ZD9331, and activity has been observed against a broad range of tumours in a number of clinical trials with these agents (Rustum et al, 1997) .
Inhibition of TS results in the depletion of intracellular dTTP and, as a result of elevated dUMP levels, an accummulation of dUTP. This nucleotide pool imbalance contributes to DNA strand breakage and cell death (Curtin et al, 1991) . Salvage of extracellular thymidine, mediated by nucleoside transport and subsequent phosphorylation by thymidine kinase, restores thymidylate pools and hence limits the activity of TS inhibitors (Jackman et al, 1984) . A number of factors may promote utilization of the salvage pathway by tumours, for example, Weber (1983) has demonstrated that the activities of the enzymes involved in nucleoside salvage can exceed those of the de novo pathway for nucleotide synthesis in a variety of tumours. Furthermore, resistance to antimetabolities mediated by nucleoside salvage may increase with malignancy (Fox et al, 1991; Kinsella and Harran, 1991) . In addition, release of nucleic acids from dead cells may result in high local concentrations of salvageable nucleosides and bases in tumours.
Salvage of pre-formed nucleosides is dependent on uptake across the plasma membrane into the cell. At physiological nucleoside concentrations the principal mode of nucleoside uptake is via the es and ei equilibrative carriers, described as such on the basis of their sensitivity (es) or insensitivity (ei) to the transport inhibitor nitrobenzylmercaptopurine riboside (NBMPR). The cardiovascular and antiplatelet drug, dipyridamole, inhibits both es and ei carriers, thereby blocking the uptake of nucleosides for salvage. Dipyridamole has been used successfully in vitro, and to a limited extent in animal studies, to increase the activity of a range of antimetabolites (reviewed in Goel and Howell, 1992) . In addition to preventing thymidine uptake, dipyridamole also enhances Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α 1 -acid glycoprotein binding the cytotoxicity of TS inhibitors by preventing the efflux of deoxyuridine, leading to a greater accumulation of dUTP (Curtin et al, 1991) . Similarly, potentiation of 5-FU cytotoxicity by dipyridamole may be mediated not only through inhibition of the uptake of thymidine for salvage, but also by the inhibition of deoxyuridine and fluorodeoxyuridine efflux, leading to higher intracellular dUMP, FdUMP and FdUTP concentrations (Grem and Fisher, 1985, 1989) .
Despite these promising in vitro data with antimetabolite/dipyridamole combinations, improved therapy in patients has not been achieved. For example, although some phase I studies suggested an enhancement of 5-FU and methotrexate activity by combination with dipyridamole (reviewed in Schmoll et al, 1990) , in phase II and III trials the combination with dipyridamole did not improve the antitumour activity of methotrexate or 5-FU (Wadler et al, 1987; Köhne-Wömpner et al, 1989) . The discrepancy between the clinical and preclinical results obtained with dipyridamole may be due to the avid binding of the drug to α 1 -acid glycoprotein (AGP), (Mahony et al, 1982) , an acute phase protein that is elevated in the plasma of cancer patients. In two studies of patients receiving the maximum tolerated dose of dipyridamole peak total plasma concentrations of dipyridamole of 12 µM and 16 µM were achieved (Willson et al, 1988; Budd et al, 1990) , concentrations which should have been sufficient to prevent nucleoside transport on the basis of in vitro data; however, the free plasma concentration of dipyridamole was only 27 nM and 38 nM in these studies, which is insufficient to enhance antimetabolite activity in vitro. In agreement with the clinical data, physiological levels of AGP have also been shown to prevent the potentiation of CB3717 growth inhibition by dipyridamole in vitro (Curtin et al, 1989) .
On the basis of in vitro data it should be possible to use nucleoside transport inhibitors to enhance the clinical activity of TS inhibitors, provided the limitations of AGP binding can be overcome. The aim of the studies described here was to investigate the effect of novel dipyridamole analogues on the in vitro growth inhibitory activity of TS. Two antifolate TS inhibitors were selected for study: the classical antifolate, CB3717 (N 10 -propargyl-5,8-dideazafolic acid), and the non-classical antifolate TS inhibitor, nolatrexed (AG337, Thymitaq, 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride) (Webber et al, 1996) . In addition, potentiation of the cytotoxicity of 5-FU was investigated. Data for selected dipyridamole analogues that are potent inhibitors of thymidine transport, even in the presence of AGP, are presented. Studies with NU3026, NU3059 and NU3060 demonstrated that the degree of enhancement of growth inhibition by TS inhibitors was dependent on the potency of the compounds as inhibitors of thymidine transport. A further inhibitor, NU3076, was identified, which was more potent than dipyridamole, active in the presence of AGP and able to potentiate both nolatrexed and 5-FU cytotoxicity.
MATERIALS AND METHODS

Drugs
CB3717 (a gift from Zeneca Pharmaceuticals, Alderley Park, UK) was dissolved in 0.15 M sodium hydrogen carbonate and stored at 4°C. Nolatrexed (a gift from Agouron Pharmaceuticals Inc, San Diego, USA), 5-FU and dipyridamole (Sigma Chemical Co, Poole, UK), NU3026, NU3059, NU3060 and NU3076 (synthesized in the Department of Chemistry, University of Newcastle upon Tyne, UK; for structures see Tables 1 and 2 ) were dissolved in dimethyl sulphoxide (DMSO) and stored at -20°C. All other chemicals were obtained from Sigma unless stated otherwise.
Cell culture
Murine leukaemia L1210 cells were used because their nucleoside transport characteristics have been well defined (Crawford et al, 1990) . Cells were maintained as exponentially growing cultures (< 8 × 10 5 cells ml -1
) in RPMI-1640 medium supplemented with 10% (v/v) fetal calf serum (Sigma), at 37°C in an atmosphere of 5% carbon dioxide in air. The cell doubling time was approximately 12 h. For growth inhibition and cytotoxicity assays, cells were adapted to grow in RPMI medium supplemented with 10% (v/v) dialysed serum (dialysed for 24 h at 4°C against two changes of 9 volumes of phosphate-buffered saline (PBS) containing 1 g activated charcoal L -1 and a further two changes of 9 volumes of PBS) to remove thymidine. Once transferred to medium containing dialysed serum cells were passaged for at least 4 weeks prior to cytotoxicity assays, when the cell doubling time was also approximately 12 h. Cells were routinely tested to exclude mycoplasma contamination (Chen, 1977) .
Nucleoside transport inhibition assay
Thymidine uptake was assayed in L1210 cells using a modification of the rapid mixing technique of Wohlheuter et al (1978) . The uptake of 100 µM thymidine by 10 6 cells was followed at 2-second intervals over a 12-second time course in the presence or absence of inhibitor in 1% or 5% (v/v) DMSO. In experiments to determine the effect of AGP, the uptake of thymidine was also measured in the presence of 5 mg ml -1 human AGP (Sigma), which is the upper limit of plasma AGP concentrations in cancer patients, i.e. approximately 125 µM (Kremer et al, 1988) .
Exponentially growing L1210 cells were washed with and resuspended in ice-cold transport buffer (130 mM sodium chloride, 5 mM potassium chloride, 1 mM magnesium chloride, 5 mM NaH 2 PO 4 , 10 mM glucose and 10 mM HEPES pH 7.4) at 2-4 × 10 7 cells ml -1
. Cells were left on ice for 30 min prior to starting the assay and then diluted further in transport buffer ± AGP (7.5 mg ml -1 ) containing 1.5% or 7.5% (v/v) DMSO (± inhibitor at 1.5 × the final concentration) for 5 min at 21°C. The suspension was mixed and 100 µl was layered onto 150 µl silicone oil (9:11 Dow Corning 556 (Sp.Gr. 0.98): Dow Corning 550 (Sp. Gr. 1.068), final Sp. Gr. 1.028) overlaying 50 µl 3 M potassium hydroxide (KOH), in six replicate 0.5 ml microfuge tubes. Transport was initiated by adding 50 µl of 300 µM thymidine in transport buffer, containing 25 µCi ml -1 [methyl- ; Amersham), to each tube in turn at 1-second intervals, giving final concentrations of: 10 6 cells in transport buffer± 5 mg ml -1 AGP, 100 µM thymidine and 1% or 5% (v/v) DMSO± inhibitor. Transport was stopped by the addition of 50 µl of400 µM dipyridamole at 1-second intervals to the tubes in reverse order. The tubes were immediately centrifuged at 12 000g for 2 min at room temperature causing the cells to pass through the oil and into the KOH. Cell number and viability in each assay was determined by haemocytometer counting using trypan blue exclusion. After centrifugation the tubes were capped and cut in the oil layer such that the bottom portion (cells solubilized in KOH) fell into a 20 ml scintillation vial. One millilitre of 0.25 M acetic acid was injected into the tube to disperse and neutralize the KOH-solubilized cells and following the addition of 10 ml of Optiphase HiSafe scintillant (Fischer Chemicals, Loughborough, UK) the radioactivity in the cells was determined by a dual label assay using an LKB-Wallac S1410 β-counter (Wallac (UK), Milton Keynes, UK). The rate of thymidine uptake in the presence and absence of inhibitor was calculated by unweighted linear regression analysis of thymidine uptake (pmol 10 -6 cells) vs time (seconds) using GraphPad PRISM TM software (GraphPad Software Inc. San Diego, CA, USA).
Inhibition kinetics
Dipyridamole and NU3076 inhibition kinetics were investigated by modifying the transport assay to measure the uptake of thymidine at concentrations ranging from 100 to 1500 µM in the presence or absence of 0.3 µM dipyridamole or NU3076. K t and T max values were calculated using the equation describing a one-site binding hyperbola, fitted using GraphPad PRISM software. The K i values for dipyridamole and NU3076 were determined by measuring the uptake of 800 µM and 400 µM thymidine in the presence of increasing concentrations of inhibitor. Cell growth was determined after 48 hour exposure to 3 µM or 10 µM CB3717 with or without 1 µM thymidine supplementation in the presence or absence of 10 µM dipyridamole, NU3026, NU3059 or NU3060. Data, normalized by comparison with cell growth in the presence of 10 µM dipyridamole, NU3026, NU3059 or NU3060 alone, are the mean of three independent observations. Standard deviations (not shown) were < 15% of the mean in each case.
Growth inhibition assays
L1210 cells in exponential growth were dispensed into each well of a 24-well plate at 10 4 cells ml -1 , in RPMI-1640 medium supplemented with (10% v/v) dialysed serum containing CB3717, with or without thymidine and/or transport inhibitor (4-6 replicate wells for each drug combination). The DMSO concentration was controlled so as to be present at 1% (v/v) in the final incubation. Replicate aliquots of the remaining cell suspension were counted to obtain a time zero cell count. After incubation at 37°C for 48 h (to allow for a minimum of three control cell doublings) cells were counted using a Coulter Counter Model Z1 (Coulter Electronics, Luton, UK). 
Cytotoxicity assay
L1210 cells adapted to grow in dialysed serum were exposed to varying concentrations of nolatrexed or 5-FU in the presence or absence of 1 µM dipyridamole or 1 µM NU3076 for 16 h in medium containing (10% v/v) dialysed serum. The cells were resuspended in fresh medium to remove the drug, counted and seeded for colony formation in 0.125% (w/v) agarose (SeaKem, Flowgen, Sittingbourne, UK) in medium supplemented with 10% (v/v) undialysed serum. To investigate prevention of thymidine rescue, L1210 cells were incubated for 16 h with a fixed concentration of nolatrexed (0, 10 or 100 µM), with or without 1 µM thymidine, in the presence or absence of 1 µM dipyridamole or NU3076, and then counted and seeded for colony formation in 0.125% (w/v) agarose as above. The enhancement factor EF 90 was calculated using the following equation: EF 90 = LC 90 nolatrexed alone/LC 90 nolatrexed + inhibitor (where LC 90 is the concentration of drug required to decrease cell survival by 90%). The enhancement factor at 50% survival, EF 50 , was calculated by substituting LC 50 values in the above equation.
RESULTS
Dipyridamole analogues with modifications of the diethanolamine side chains
Inhibition of thymidine uptake The inhibition of thymidine uptake by three novel compounds (NU3026, NU3059 and NU3060), with different substituents at the 2,6-position of the pyrimidopyrimidine ring was determined, and inhibition at concentrations of 1 and 10 µM of these inhibitors, as Table 1 . All three compounds were less potent than dipyridamole in the absence of AGP. However, in the presence of 5 mg ml -1 AGP, dipyridamole was inactive as an inhibitor of thymidine uptake, whereas all of the novel compounds retained significant activity.
Potentiation of the growth inhibition produced by the TS inhibitor, CB3717
The inhibition of the growth of L1210 cells by CB3717, with or without 1 µM thymidine, determined in the presence or absence of 10 µM nucleoside transport inhibitor is shown in Figure 1 . All the inhibitors potentiated growth inhibition produced by 3 µM CB3717 in the absence of salvageable thymidine, and also prevented thymidine rescue from CB3717-induced growth inhibition. Comparable results were obtained by combining the transport inhibitors with 10 µM CB3717 (Table 2) . Similarly, there was a modest potentiation of CB3717 growth inhibition by 1 µM dipyridamole, NU3059 and NU3026 and partial reversal of thymidine rescue by 1 µM dipyridamole and NU3059 (data not shown). For both potentiation of CB3717-induced growth inhibition and prevention of thymidine rescue the rank order of potency of the compounds was: dipyridamole > NU3059 > NU3026 > NU3060. Comparison of the inhibitory effect of 10 µM inhibitor on nucleoside transport (Table 1) with the effect on cell growth (in the presence of CB3717 + TdR) demonstrated a significant positive rank correlation (Spearman's rank correlation coefficient = 0.9, P = 0.083).
A dipyridamole analogue modified at the 4,8-position (NU3076)
Inhibition of thymidine uptake in the presence and absence of AGP In an attempt to identify a potent dipyridamole analogue completely devoid of AGP binding, synthetic efforts were directed at replacing the 4,8-piperidino group of dipyridamole with other moieties. These modifications led to the identification of NU3076. As shown in Table 3 , NU3076 was at least as potent as dipyridamole and AGP (5 mg ml -1 ) did not significantly reduce the inhibition of thymidine uptake at either 10 µM or 1 µM NU3076 (equivalent to a 12-and 120-fold molar excess of AGP respectively). In contrast, AGP at this concentration abolished the inhibition of thymidine uptake by both 1 µM and 10 µM dipyridamole. NU3076 was therefore selected for further investigation and comparison with dipyridamole. Inhibition kinetics Kinetic measurements were performed to determine the mechanism responsible for the inhibition of thymidine uptake by dipyridamole and NU3076. The apparent K t and T max of nucleoside transport in L1210 cells was calculated in the absence and in the presence of 0.3 µM dipyridamole or 0.3 µM NU3076, Figure 2 and Table 4 . There was a significant decrease in the apparent T max for thymidine transport in the presence of 0.3 µM dipyridamole and NU3076 (P = 0.006 and P = 0.015 respectively). The apparent K t values were only marginally different from the control value (P = 0.083 and 0.069 for 0.3 µM dipyridamole and NU3076 respectively). When compared to control values, a significant decrease in the T max /K t ratio was observed with both dipyridamole and NU3076, indicative (together with a decrease in T max ) of mixed inhibition. The K i values for dipyridamole and NU3076 were determined, using Dixon plots at thymidine concentrations of 400 and 800 µM, the K i for dipyridamole and NU3076 were estimated to be 0.28 µM and 0.1 µM respectively (Figure 3 ).
Potentiation of TS inhibitor cytotoxicity
Neither 1 µM NU3076 nor 1 µM dipyridamole were cytotoxic per se against L1210 cells (cell survival ± standard error of 100 ± 24% and 100 ± 19% respectively). The clonogenic survival of L1210 cells exposed to varying concentrations of nolatrexed in the absence of thymidine, and in the presence or absence of 1 µM of dipyridamole or NU3076 is shown in Figure 4 , corresponding LC 50 and LC 90 values are given in Table 5 . NU3076 and dipyridamole at 1 µM produced equivalent potentiation of nolatrexed cytotoxicity ( Figure 4 and Table 5 ) and, as cells were exposed to nolatrexed in medium supplemented with dialysed serum, potentiation by dipyridamole and NU3076 was not due to the prevention of thymidine rescue. Thymidine rescue from nolatrexed cytotoxicity in L1210 cells in the presence and absence of dipyridamole and NU3076 was also investigated. The cytotoxic effect of 10 µM nolatrexed was completely prevented by supplementing the medium with 1 µM thymidine and both dipyridamole and NU3076 at 1 µM were equi-active in preventing thymidine rescue, which was reduced but not blocked completely ( Figure 5 ). In the presence of 10 µM dipyridamole thymidine rescue was completely blocked; the survival of cells exposed to nolatrexed and thymidine in the presence of 10 µM dipyridamole being equivalent to that of cells exposed to nolatrexed alone ( Figure 5) . It was not possible to investigate the prevention of thymidine rescue by 10 µM NU3076 due to the limited solubility of the analogue. The effect of 1 µM dipyridamole or 1 µM NU3076 on the cytotoxicity of 5-FU was also determined. A representative survival curve is shown in Figure 6 , and pooled LC 50 and LC 90 data (from three independent experiments) are given in Table 5 . Significant potentiation of 5-FU cytotoxicity by dipyridamole and NU3076 was observed at high concentrations of 5-FU (30 µM and 100 µM) but at lower concentrations the potentiation was not significant. NU3076 also significantly reduced the IC 90 concentration of FU. These experiments were conducted in the absence of salvageable thymidine (dialysed serum) and hence potentiation was presumably due to inhibition of nucleoside efflux (deoxyuridine, fluorodeoxyuridine and/or fluorouridine) although this was not determined experimentally.
DISCUSSION
Three dipyridamole analogues with altered 2,6-substituents (NU3026, NU3059 and NU3060) have been identified which, although less potent than dipyridamole in the absence of AGP, retain significant activity in the presence of this plasma protein. The three analogues were compared with dipyridamole as modulators of CB3717-induced growth inhibition and, in the absence of salvageable thymidine, all of the analogues increased the growth inhibitory effect of CB3717. In the absence of thymidine the potentiation of CB3717 activity was probably due to the inhibition of deoxuridine efflux, which has been shown in the case of dipyridamole to result in greater dUTP accumulation and DNA strand breakage (Curtin et al, 1991) . All three dipyridamole analogues were also able to block thymidine rescue from CB3717-induced growth inhibition to a degree that was related to their potencies as inhibitors of nucleoside transport.
Substitution of the 4,8-piperidino groups of dipyridamole with a p-methoxybenzylamino group, as in the case of NU3076, resulted in both improved potency as a nucleoside transport inhibitor and reduced susceptibility to AGP binding. Notably, the activity of NU3076 was not significantly affected by a > 100-fold molar excess of AGP whereas the activity of dipyridamole was abolished under equivalent conditions. The kinetic parameters calculated in this study for thymidine uptake by L1210 cells, and the K i for dipyridamole are comparable to reported values (Plagemann and Wohlhueter, 1984) . Both dipyridamole and NU3076 were found to exhibit mixed-type inhibition, indicating that the interaction with the nucleoside transporter is more complex than simple competition between dipyridamole and nucleosides for the substrate binding site, again in agreement with previous observations (Woffendin and Plagemann, 1987) . Dipyridamole-sensitive nucleoside transport is mediated by equilibrative transporters, of which there are two subtypes (es and ei) which exhibit different kinetic properties (Jarvis, 1986; Plagemann et al, 1988; Hammond, 1991) and are the product of distinct genes (Griffiths et al, 1997; Crawford et al, 1998) . The proportion of carriers expressed in the L1210 cells used in these studies was found to be about 70% es, and 30% ei (K Bowman, unpublished data), in agreement with published data (Belt, 1983) . The affinity of dipyridamole for the es transporter is probably 2.5 × higher than for the ei transporter (Hammond, 1991) , producing different inhibition constants for each transporter subtype. Thus, the mixed-type inhibition of thymidine uptake observed with dipyridamole and NU3076 in L1210 cells may reflect the presence of the two different transporter proteins.
Both nolatrexed and 5-FU were cytotoxic to L1210 cells in a concentration-dependent manner. The observation that 1 µM thymidine completely reversed the cytotoxic effects of nolatrexed in L1210 cells confirms that TS is the locus of action of the drug in these cells, as has been demonstrated in other cell lines (Webber et al, 1996) . Cell survival decreased in response to increasing concentrations of nolatrexed, with only 10-20% of cells surviving exposure to 10 µM nolatrexed. At concentrations above 10 µM nolatrexed there was very little further increase in cytotoxicity, suggesting a fraction of the cells are resistant to inhibition of TS, probably because they failed to enter a nolatrexed-sensitive phase of the cell cycle during the period of drug exposure. Cell killing also increased in response to increasing 5-FU concentrations; however, in contrast to the pattern of cytotoxicity of nolatrexed, there was no apparent plateau in cell survival. The lack of a resistant fraction of cells may reflect the fact that 5-FU has a number of loci of action in addition to TS inhibition, e.g. FUTP and FdUTP incorporation into RNA and DNA respectively.
Both dipyridamole and the novel analogue NU3076 were approximately equipotent as enhancers of the cytotoxicity of nolatrexed and 5-FU and, since the clonogenic cell survival studies were carried out in medium supplemented with dialysed serum, potentiation by dipyridamole and NU3076 was not due to inhibition of thymidine rescue. By analogy with previous studies (Grem and Fischer 1985, 1989; Curtin et al, 1988 Curtin et al, , 1991 potentiation in the absence of thymidine is most likely to be due to inhibition of nucleoside efflux (deoxuridine, fluorodeoxuridine, fluorouridine) leading to greater accumulation of cytotoxic nucleosides. Modulation of thymidine rescue from nolatrexed cytotoxicity by dipyridamole and NU3076 was also investigated, and the complete reversal of nolatrexed cytotoxicity by 1 µM thymidine was partially inhibited by both 1 µM dipyridamole and NU3076, and completely blocked by 10 µM dipyridamole. In nucleoside transport assays thymidine uptake was inhibited by 80% at 1 µM dipyridamole and by 56% at 1 µM NU3076, consistent with the partial rescue from nolatrexed cytotoxicity at this concentration. In the presence of 10 µM dipyridamole, which produced 99% inhibition of thymidine uptake in transport studies, thymidine rescue was completely blocked such that the survival of cells exposed to nolatrexed, thymidine and 10 µM dipyridamole was not significantly different from that of cells exposed to nolatrexed alone. It was not possible to investigate the prevention of thymidine rescue by 10 µM NU3076 due to the limited solubility of this compound. Recent data from this laboratory (P Smith, manuscript in preparation) indicate that NU3076 can block thymidine rescue from TS inhibitor cytotoxicity in human cancer cell lines.
Both dipyridamole and NU3076 potentiated 5-FU cytotoxicity to a similar extent. However, potentiation was only apparent at high concentrations of 5-FU, and the degree of potentiation of 5-FU was less than that observed for nolatrexed. In other studies dipyridamole has been shown to potentiate 5-FU cytotoxicity by different mechanisms in different cell lines. In WiDr human colon adenocarcinoma cells, dipyridamole potentiated 5-FU cytotoxicity by depletion of cellular dTTP pools (Lonn et al, 1989) . In HCT 116 cells, the potentiation of 5-FU by dipyridamole was considered to be a consequence of both elevated dUMP levels and increased intracellular accumulation of FdUMP, the latter formed from FUdR. These nucleotide pool changes were thought to reflect the combined effects of de-repression of dCMP deaminase and thymidine kinase, following loss of feedback inhibition by dTTP, and inhibition of deoxyuridine and fluorodeoxuridine efflux (Grem and Fisher, 1985, 1989 ). An investigation into which of these mechanisms is critical to 5-FU cytotoxicity in L1210 cells has not been undertaken, but clearly TS inhibition is not the only important locus of action of the drug.
From the data reported here it is apparent that AGP binding, which has limited the clinical use of dipyridamole as an enhancer of antimetabolite chemotherapy, can be overcome. Potentiation of the growth inhibition and cytotoxicity of TS inhibitors by novel dipyridamole analogues was related to nucleoside transport inhibitory potency. All of the compounds described here were more potent than dipyridamole in the presence of physiological concentrations of AGP, and the potency of one compound, NU3076, was not significantly affected by AGP binding.
